Electrophysiological studies on the effects of mianserin, a tetracyclic antidepressant agent, on isolated guinea-pig papillary muscle. 1988

T Kinugawa, and H Kotake, and S Hirai, and J Miyamoto, and O Igawa, and J Hasegawa, and H Mashiba
1st Department of Internal Medicine, Tottori University, Yonago, Japan.

We studied the effects of mianserin on the action potentials of papillary muscle from the guinea-pig. Mianserin (above 10 microM) reduced the maximum rate of the rise (Vmax) of the action potential, and shifted the Vmax-Em relationship to more negative potentials. The compound also depressed the slow action potentials of K+-depolarized papillary muscles. It is concluded that relatively high concentrations of mianserin had an inhibitory action on the electrophysiological properties of both the fast- and slow-response fibers of the heart.

UI MeSH Term Description Entries
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D008803 Mianserin A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors. Lerivon,Mianserin Hydrochloride,Mianserin Monohydrochloride,Org GB 94,Tolvon,Hydrochloride, Mianserin,Monohydrochloride, Mianserin
D010210 Papillary Muscles Conical muscular projections from the walls of the cardiac ventricles, attached to the cusps of the atrioventricular valves by the chordae tendineae. Muscle, Papillary,Muscles, Papillary,Papillary Muscle
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D000200 Action Potentials Abrupt changes in the membrane potential that sweep along the CELL MEMBRANE of excitable cells in response to excitation stimuli. Spike Potentials,Nerve Impulses,Action Potential,Impulse, Nerve,Impulses, Nerve,Nerve Impulse,Potential, Action,Potential, Spike,Potentials, Action,Potentials, Spike,Spike Potential
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

T Kinugawa, and H Kotake, and S Hirai, and J Miyamoto, and O Igawa, and J Hasegawa, and H Mashiba
February 1988, Journal of cardiovascular pharmacology,
T Kinugawa, and H Kotake, and S Hirai, and J Miyamoto, and O Igawa, and J Hasegawa, and H Mashiba
August 1997, General pharmacology,
T Kinugawa, and H Kotake, and S Hirai, and J Miyamoto, and O Igawa, and J Hasegawa, and H Mashiba
February 1985, European journal of pharmacology,
T Kinugawa, and H Kotake, and S Hirai, and J Miyamoto, and O Igawa, and J Hasegawa, and H Mashiba
January 1984, Journal of cardiovascular pharmacology,
T Kinugawa, and H Kotake, and S Hirai, and J Miyamoto, and O Igawa, and J Hasegawa, and H Mashiba
October 1993, Circulation,
T Kinugawa, and H Kotake, and S Hirai, and J Miyamoto, and O Igawa, and J Hasegawa, and H Mashiba
May 1993, Neuropeptides,
T Kinugawa, and H Kotake, and S Hirai, and J Miyamoto, and O Igawa, and J Hasegawa, and H Mashiba
April 1983, Naunyn-Schmiedeberg's archives of pharmacology,
T Kinugawa, and H Kotake, and S Hirai, and J Miyamoto, and O Igawa, and J Hasegawa, and H Mashiba
March 1992, The Journal of pharmacy and pharmacology,
T Kinugawa, and H Kotake, and S Hirai, and J Miyamoto, and O Igawa, and J Hasegawa, and H Mashiba
July 1979, Psychopharmacology bulletin,
T Kinugawa, and H Kotake, and S Hirai, and J Miyamoto, and O Igawa, and J Hasegawa, and H Mashiba
January 1989, General pharmacology,
Copied contents to your clipboard!